UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): September 14, 2021

 

AzurRx BioPharma, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-37853

 

46-4993860

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

777 Yamato Road, Suite 502

Boca Raton, Florida

 

33431

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (561) 589-7020

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

AZRX

 

Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

  

Item 7.01. Regulation FD Disclosure.

 

On September 14, 2021, AzurRx BioPharma, Inc. (the “Company”) issued a press release containing a letter addressed to the Company’s shareholders and the investment community from the Company’s Chair of the Board of Directors, President and Chief Executive Officer, James Sapirstein. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

Item 9.01. Financial Statements and Exhibits.

 

(d)

Exhibit No.

 

Description

 

99.1

 

Press Release, dated September 14, 2021.

 

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

2

 

   

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

AzurRx BioPharma, Inc.

 

 

 

 

 

September 14, 2021

By:

/s/ Daniel Schneiderman

 

 

Name:

Daniel Schneiderman

 

 

Title:

Chief Financial Officer

 

 

 

3

 

AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more AzurRx BioPharma Charts.
AzurRx BioPharma (NASDAQ:AZRX)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more AzurRx BioPharma Charts.